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Abstract
Background: Rift Valley fever virus (RVFV) remains heavily neglected in humans in Mozambique, even though
recent outbreaks were reported in neighboring countries in humans and several cases of RVFV in cattle were
reported in several districts in Mozambique.
Findings: We conducted a cross sectional study during and after severe flooding that occurred in 2013 in
Mozambique. Paired acute and convalescent serum samples were tested from febrile patients attending a primary
health care unit in a suburban area of Maputo city for the presence of IgG and IgM antibodies against Rift Valley
fever virus (RVFV) using enzyme-linked immunosorbent assay (ELISA). Seroconversion of IgG anti-RVFV was observed
in 5 % (10/200) of convalescent patients and specific IgM anti-RVFV was detected in one acute patient (0.5 %;
1/200). All sera from acute patient tested negative by real time PCR.
Conclusion: In conclusion, our results suggest that RVF represent an important but neglected cause of febrile
illness following periods of flooding in southern Mozambique.
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Introduction
Rift Valley Fever Virus (RVFV) is a mosquito borne zoo-
notic virus that has emerged as an important cause of fe-
brile illness in several sub-Saharan countries [1–5],
including those that share their borders with Mozambique,
such as Tanzania and South Africa [4, 6–8]. The likelihood
that RVF also causes disease in humans in Mozambique is
high because of the geographical proximity, environmental
similarities and frequent trade between Mozambique and
these countries. In Mozambique, RVFV in humans has
been poorly studied and only one study was conducted
more than 30 years ago among healthy pregnant women
and found a RVFV prevalence of 2 % [6]. Since then, no
other study was conducted in humans in Mozambique.
Recent publications demonstrated that anti-RVFV IgG
was often detected in cattle in Maputo and Gaza Province,
both situated in the southern Mozambique [9–11], and in
two rural villages in the center of the country [12]. This
reinforces the concern that RVFV may be causing undiag-
nosed disease in humans in Mozambique, particularly in
places where recent cases of RVFV were reported in cattle
[10–12]. The risk of outbreaks of RVFV in Mozambique is
substantial, as the country is ranked the third most
* Correspondence: esamogudojr@gmail.com
1National Institute of Health, Ministry of Health, Av Eduardo Mondlane 1008,
Ministry of Health Main Building, 2nd floor, PO Box 264, Maputo,
Mozambique
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gudo et al. Virology Journal  (2016) 13:96 
DOI 10.1186/s12985-016-0542-2
vulnerable country in Africa to extreme weather events.
Indeed the frequency of floods increased in the last two
decades [13] and it is well known that outbreaks of RVFV
commonly coincide with periods of heavy rainfall [14, 15].
Lastly, clinical presentation of RVFV resembles that of
malaria, leading to misdiagnosis of malaria, mistreatment
with anti-malarial drugs [16] and inappropriate manage-
ment of febrile illness. Given this gap in the literature, we
conducted this study with the aim to investigate the bur-
den of RVFV in febrile patients in southern Mozambique
during and after the heavy rainfall and flooding that
occurred in 2013.
Methods
Study design and study setting
A cross-sectional study was conducted at the Mavalane
Health Center, a primary health care facility situated in
southern Mozambique. This health facility serves a large
suburban area in Maputo City with a total surface area
is 108 km2 and a total population of 293 361 habitants
(see Fig. 1). The households are precarious and sanita-
tion is poor. In Maputo, the rainy season runs from No-
vember through March. The southern region of
Mozambique including the study area was heavily af-
fected by intense rainfalls between January and March
2013, which resulted in flooding in several areas. Rain-
falls in this period reached up to 300 mm within
10 days.
All patients attending this health facility between Janu-
ary and September 2013 with acute febrile syndrome
(axillary temperature > 37.5 °C) and age > 5 years were
invited to participate. Written consent was requested
prior to enrollment. This study was approved by the
National Bioethical Committee in Mozambique (Ref:
IRB00002657) prior to initiation. Exclusion criteria
included, pregnancy, presence of psychiatric disease and
febrile disease with a readily identifiable focus of infec-
tion, such as otitis media, sinusitis, purulent pharyngitis,
cellulitis, urinary tract infection, dental abscess, septic
arthritis, pneumonia or pelvic inflammatory disease.
Fig. 1 Geographical representation of study area. a shows the geographical localization of Mozambique in south east Africa (Mozambique is highlighted
in pink in the small map of Africa) and map of Mozambique (larger map). Coloured districts in Mozambique map, represents districts where cases of
RVFV were previously reported in Cattle. b is the representation of the neighborhood of Mavalane health area covered by the Mavalane health center.
Mavalane health area comprises two geographical and well delimited areas, namely, Mavalane “A” (yellow) and Mavalane “B” (red) neighborhood
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Sample collection
A total volume of 10 mL of blood was requested from
each volunteer during the enrollment visit (acute sam-
ple) and collected into K3EDTA tube (5 ml) and into
serum separation tube (5 ml, both from BD Vaccutainer,
USA). All participants were requested to return to the
health facility three weeks later for follow up and collection
of additional 5 mL of blood (convalescent sample) into
K3EDTA tube.
Questionnaire
A standardized questionnaire was used to collect clin-
ical, demographic and epidemiological data, including
information on risk factors for RVFV infection.
Laboratory testing
Blood smear microscopy
Acute sample drawn from each participant was tested
for malaria using blood smear microscopy. A thick blood
smear was mounted from anticoagulated whole blood.
All blood smears were stained using the Giemsa proto-
col and screened for Plasmodium falciparum, P.malarie,
P. ovale and P. vivax using light microscopy. Parasite
density was estimated by means of a semi-quantitative
scale [17].
Rift Valley fever virus serology and TaqMan probe-based
one-step real-time RT-PCR
Samples were shipped and tested at The Center for
Emerging and Zoonotic Diseases of the National Insti-
tute for Communicable Diseases, National Health La-
boratory Service (NICD/NHLS) in South Africa. The
testing algorithm was as follows, at first, all convalescent
serum samples were initially tested using recombinant
nucleoprotein (rNP)-based anti-RVFV IgG ELISA [18].
If the convalescent sample was positive, the correspond-
ing acute sample was screened using the same test. Pa-
tients with evidence of seroconversion for anti-RVFV
IgG antibodies, were classified as acute RVFV infection.
In order to confirm the presence of acute infection,
acute serum samples, from seroconverting patients were
screened using anti-RVFV IgM ELISA [19] and for
RVFV RNA using TaqMan probe-based one-step real-
time RT-PCR [20] targeting the RVFV Gn gene. RNA
was extracted from sera using a QIAamp viral RNA mini
kit (QIAGEN, Germany) as per manufacturer’s instruc-
tions. Acute samples were tested for IgM because our
previous research showed that these antibodies were
detectable as early as 3-4 days post experimental infec-
tion in sheep [19, 21] and 6 days post administration of
RVFV vaccine in humans [19]. Previous RVFV exposure
was defined as presence of anti-RVFV IgG antibodies,
both in the acute and convalescent visit. Negative anti-
RVFV infection was defined as an absence of IgG anti-
RVFV antibodies in the convalescent serum sample.
For ELISA testing, we followed strictly the instructions
described in published literature and details of the test-
ing procedures and interpretation of IgM and IgG
assays, are described in the two published manuscripts
[18, 19]. The sensitivity and specificity of anti-RVFV IgG
ELISA was 99.7 and 99.6 %, respectively and cut off was
set at 28.98 percentage of positivity of internal high posi-
tive control (PP) [18]. The sensitivity anti-RVFV IgM
ELISA was 100 % as early as 4 days post infection and
the specificity was 99.6 % and cut off was set at 7.1 PP
[19]. PP is calculated using the following formula: (mean
net OD of test sample/mean net OD of high-positive
control)/100.
Data analysis
Data analysis was performed using the statistics package
STATA 9.0 (College Station, Texas: StataCorp, USA,
2005). Simple frequencies were calculated for each study
variable. Study groups were compared using Kruskal
Wallis test. Associations between categorical variables
were determined using logistic regression analysis. A p
value < 0.05 was considered of statistical significance.
Results
Three hundred and seventy five patients were enrolled
between January and September 2013 and 175 did not
return to their convalescent visit (see Fig. 2), although
efforts were undertaken by the research team to reach
them by phone a few days prior to the expected date of
convalescent appointment. Of note, the average number
of days between onset of fever and recruitment and con-
valescent visit were 1 day and 25 days, respectively.
The median age of study participants was 28 years
(IQR: 21-36 years) and 56.7 % (98/173) were female.
Of the 200 convalescent samples, 10 % (20/200) tested
positive for IgG anti-RVFV. Seroconversion for IgG anti-
RVFV was confirmed in 10 (5.0 %, 10/200) samples.
Most of samples from patients with serological evidence
of acute infections (defined as presence of seroconver-
sion of IgG anti-RVFV antibodies between acute and
convalescent sample), were clustered between February
and April with a peak in April (see Table 1). The corre-
sponding acute sample from seroconverting patients,
were additionally tested for the presence of IgM anti-
RVFV and one (0.5 %, 1/200) was positive. In term of
diagnostic and therapeutic implications, 6 out of 9
(67 %) patients who met the case definition for acute
RVFV infection were misdiagnosed as malaria and
treated with anti malarial medication (see Table 1).
Real-time PCR was performed on sera from 10
patients with serological evidence of acute RVFV infec-
tion and all were negative.
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A total of 36 out of 375 patients enrolled were positive
for malaria, yielding a prevalence rate of 9.6 %. Co-
infection with RVFV and malaria were not found among
those patients.
Based on the serological profile, patients were strati-
fied into three main groups, namely i) acute RVFV infec-
tion if they seroconverted for anti-RVFV IgG antibodies
between the acute and convalescent visit (10/200, 5.0 %),
ii) previous RVFV exposure if they presented anti-RVFV
in both the acute and convalescent visit (10/200, 5.0 %)
and iii) no anti-RVFV antibodies (180/200, 90.0 %).
Table 2 shows that the three groups were similar in term
of age, gender and clinical presentation. Chills and ab-
dominal pain were the most common clinical presenta-
tion. No severe case was reported and no patients
presented any form of hemorrhage, neurological sign or
blindness
Discussion
To our knowledge this is the first investigation of RVFV
among febrile patients in Mozambique and we found that
5 % (10/200) of febrile patients seroconverted to IgG anti-
bodies against RVFV between their acute and convalescent
samples. Although novel for Mozambique, this finding is
not surprising, based on the following arguments: i) A
recent study conducted by our group in the same area
showed that Aedes mosquitoes were abundant [22] ii)
recent studies conducted in several districts in the sur-
roundings of the study area found elevated frequencies of
anti-RVFV IgG antibodies in cattle [10, 11], iii) several
Fig. 2 Participant’s recruitment and sample testing. Out of 375 patients recruited, 200 returned to the convalescent visit of which 20 were positive (10.0 %).
The corresponding 20 acute samples of those patients were screened using anti-RVFV IgG ELISA. Evidence of seroconversion could be demonstrated in 10
(5.0 %) out of 20 of those patients. Amongst 10 patients who seroconverted for IgG anti-RVFV, only one tested positive the presence of anti-RVFV
IgM antibody
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outbreaks and sporadic cases have been reported in coun-
tries neighboring Mozambique such as South Africa and
Tanzania [4, 8, 23], iv) patients were recruited during and
after the severe heavy rainfalls that occurred in southern
Mozambique in 2013 [8, 15], v) people living in the study
area travel regularly to the surroundings districts where
elevated frequencies of antibodies were recently docu-
mented in cattle [10, 11] and vi) cattle population is much
more frequent than sheep in the study area [24]. Although
the source of infection was not investigated in this study,
the fact that most of cases occurred between February
through May, peaking in April, suggest that heavy rainfall
and floods that occurred in the same period might have
influenced the occurrence of RVFV in Mozambique. No
entomological or livestock investigation was performed as
this was an exploratory study. We acknowledge that lack of
this information is a limitation. We plan to incorporate
these components into a forthcoming investigation.
Only 1 patient was positive for anti-RVFV IgM anti-
bodies in the acute sample. This may be explained by
Table 1 Chronological information and laboratory results of the 10 patients with serological evidence of acute RVFV infection
















1 Feb 23, 2013 Feb 24, 2013 1 yes - - - Yes
2 Feb 26, 2013 Feb 27, 2013 1 yes - - - Yes
3 Apr 17, 2013 Apr 18, 2013 1 yes - - - No
4 Apr 23, 2013 Apr 23, 2013 <1 yes - - - Yes
5 Apr 26, 2013 Apr 26, 2013 <1 yes - - - Yes
6 Apr 27, 2013 Apr 27, 2013 <1 yes - - - No
7 Apr 27, 2013 Apr 29, 2013 2 yes + - - Yes
8 May 10, 2013 May 11, 2013 1 yes - - - NA
9 May 11, 2013 May 12, 2013 1 yes - - - Yes
10 July 17, 2013 July 19, 2013 2 yes - - - No
#days: between onset disease and sample collection, np not performed, NA not available
aSeroconversion is defined as IgG anti-RVFV level below ELISA cut-off in the acute serum and above ELISA cut-off in convalescent serum
Table 2 Clinical and demographic characteristics of study participants stratified by RVFV infection status
Socio-demographic
characteristics
Acute RVFV Infection Previous RVFV exposure No RVFV antibodies p-
valuen (%) n (%) n (%)
Total n = 10 n = 10 n = 190
Age
Median 30 23 28 0.202
IQR 19-42 19-30 21-35
Gender
Male 6 (60.0) 5 (50.0) 80 (44.4) 0.603
Female 4 (40.0) 5 (50.0) 100 (55.6)
Recent contact with cattle 5 (50.0) 4 (40.0) 51 (28.3) 0.136
Recent international travel 1 (10.0) 0 12 (6.7) 0.636
Chills 8 (80.0) 7 (70.0) 106 (58.9) 0.339
Pruritus 1 (10.0) 0 19 (10.6) 0.556
Headache 9 (90.0) 8 (80.0) 131 (73.2) 0.454
Arthralgia 5 (55.6) 17 (38.6) 46 (30.1) 0.192
Skin Rash 0 1 (10.0) 47 (8.9) 0.609
Myalgia 5 (50.0) 6 (60.0) 77 (42.7) 0.524
Abdominal pain 6 (60.0) 7 (70.0) 81 (45.0) 0.213
Vomiting 2 (20.0) 1 (10.0) 131 (17.2) 0.812
Diarrhea 2 (20.0) 2 (20.0) 21 (11.7) 0.872
Hemorrhage 0 0 0 -
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the fact that the average number of days between onset
of fever and blood collection was one day, and two pa-
tients were enrolled two days post onset of fever, likely,
before the seroconversion of IgM antibodies. IgM anti-
RVFV was not performed in the convalescent samples
and we acknowledge this as a limitation of our study,
but the demonstrated seroconversion for IgG antibodies
against RVFV should be regarded as evidence for recent
exposure to RVFV. The anti-RVFV IgG ELISA was in-
tensively validated according to the results of a virus
neutralization test in 2967 sera collected in Africa and
was shown to have diagnostic sensitivity and sensitivity
close to 100 % [18, 19].
PCR results were all negative. Negative PCR results
might be attributed to the fact that viremia in these pa-
tients is transient. We also argue that PCR results might
be explained by the fact that serum samples were poorly
handled, by repetitive and multiple freeze-thaw cycles
and long periods of storage at room temperature, result-
ing in degradation of the RNA or viral particles.
No cases of severe diseases was reported and this
might be explained by the fact that patients were re-
cruited at the outpatient triage at the primary health
care facility, where the majority of patients presents with
non-severe disease.
Of remark, our data showed that 67 % of patients with
serological evidence of acute RVFV infection and nega-
tive malaria blood smear were treated with antimalarial
drugs. This demonstrates that most of RVFV infections
are misdiagnosed as malaria.
Conclusion
In conclusion, our data suggests that RVFV infection oc-
curs among febrile patients in the periods of heavy rain-
falls and flooding in southern Mozambique and that
most of cases are misdiagnosed as malaria, leading to
mistreatment with antimalarial drugs.
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